Targeted killing of colorectal cancer cell lines by a humanised IgG1 monoclonal antibody that binds to membrane-bound carcinoembryonic antigen

British Journal of Cancer

Volumn 98, Issue 7, 2008, Pages 1217-1225

  Conaghan, P J ^a,b   Ashraf, S Q ^a,b   Tytherleigh, M G ^a,b   Wilding, J L ^a   Tchilian, E ^a   Bicknell, D ^a   Mortensen, N J Mc C ^b   Bodmer, W F ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

ADCC; CEA; Colorectal cancer; PR1A3

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CD16 ANTIGEN; CD16A ANTIGEN; IMMUNOGLOBULIN G1 ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; BINDING ASSAY; CANCER CELL CULTURE; COLORECTAL CANCER; CONTROLLED STUDY; CYTOTOXICITY; DRUG BINDING; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; HUMAN; HUMAN CELL; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIBODY SPECIFICITY; ANTIGEN-ANTIBODY COMPLEX; ANTIGENS, NEOPLASM; ANTIGENS, SURFACE; CARCINOEMBRYONIC ANTIGEN; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; CYTOTOXICITY, IMMUNOLOGIC; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN G; KILLER CELLS, NATURAL; RECEPTORS, IGG;

EID: 41649116865     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604289     Document Type: Article

References (46)

1. Adams GP, Schier R, McCall AM, Simmons HH, Horak EM, Alpaugh RK, Marks JD, Weiner LM (2001) High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res 61: 4750-4755
2. Allum WH, MacDonald F, Anderson P, Fielding JW (1986) Localisation of gastrointestinal cancer with a 131 I labelled monoclonal antibody to CEA. Br J Cancer 53: 203-210
3. Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, Migeon C, Cabaret V, Fermeaux V, Bertheau P, Garnier J, Jeannin JF, Coudert B (2006) Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer 94: 259-267
4. Berinstein NL (2002) Carcinoembryonic antigen as a target for therapeutic anticancer vaccines: a review. J Clin Oncol 20: 2197-2207
5. Blomberg K, Hautala R, Lovgren J, Mukkala VM, Lindqvist C, Akerman K (1996) Time-resolved fluorometric assay for natural killer activity using target cells labelled with a fluorescence enhancing ligand. J Immunol Methods 193: 199-206
6. Boyum A (1968) Separation of leukocytes from blood and bone marrow. Introduction. Scand J Clin Lab Invest Suppl 97: 7
7. Brattain MG, Fine WD, Khaled FM, Thompson J, Brattain DE (1981) Heterogeneity of malignant cells from a human colonic carcinoma. Cancer Res 41: 1751-1756
8. Browning MJ, Krausa P, Rowan A, Hill AB, Bicknell DC, Bodmer JG, Bodmer WF (1993) Loss of human leukocyte antigen expression on colorectal tumor cell lines: implications for anti-tumor immunity and immunotherapy. J Immunother 14: 163-168
9. Carter PJ (2006) Potent antibody therapeutics by design. Nat Rev Immunol 6: 343-357
10. Chan CH, Stanners CP (2007) Recent advances in the tumour biology of the GPI-anchored carcinoembryonic antigen family members CEACAM5 and CEACAM6. Curr Oncol 14: 70-73
11. Chau I, Allen MJ, Cunningham D, Norman AR, Brown G, Ford HE, Tebbutt N, Tait D, Hill M, Ross PJ, Oates J (2004) The value of routine serum carcino-embryonic antigen measurement and computed tomography in the surveillance of patients after adjuvant chemotherapy for colorectal cancer. J Clin Oncol 22: 1420-1429
12. Clynes R (2006) Antitumor antibodies in the treatment of cancer: Fc receptors link opsonic antibody with cellular immunity. Hematol Oncol Clin North Am 20: 585-612
13. Clynes R, Takechi Y, Moroi Y, Houghton A, Ravetch JV (1998) Fc receptors are required in passive and active immunity to melanoma. Proc Natl Acad Sci USA 95: 652-656
14. Colcher D, Esteban JM, Carrasquillo JA, Sugarbaker P, Reynolds JC, Bryant G, Larson SM, Schlom J (1987) Quantitative analyses of selective radiolabeled monoclonal antibody localization in metastatic lesions of colorectal cancer patients. Cancer Res 47: 1185-1189
15. Delaloye B, Bischof-Delaloye A, Buchegger F, von Fliedner V, Grob JP, Volant JC, Pettavel J, Mach JP (1986) Detection of colorectal carcinoma by emission-computerized tomography after injection of 123I-labeled Fab or F(ab')2 fragments from monoclonal anti-carcinoembryonic antigen antibodies. J Clin Invest 77: 301-311
16. Durbin H, Bodmer WF (1987) A sensitive micro-immunoassay using beta-galactosidase/ anti-beta-galactosidase complexes. J Immunol Methods 97: 19-27
17. Durbin H, Young S, Stewart LM, Wrba F, Rowan AJ, Snary D, Bodmer WF (1994) An epitope on carcinoembryonic antigen defined by the clinically relevant antibody PR1A3. Proc Natl Acad Sci USA 91(10): 4313-4317
18. Epenetos AA, Canti G, Taylor-Papadimitriou J, Curling M, Bodmer WF (1982) Use of two epithelium-specific monoclonal antibodies for diagnosis of malignancy in serous effusions. Lancet 2: 1004-1006
19. Epenetos AA, Snook D, Durbin H, Johnson PM, Taylor-Papadimitriou J (1986) Limitations of radiolabeled monoclonal antibodies for localization of human neoplasms. Cancer Res 46: 3183-3191
20. Fogh J, Trempe G (1975) Human Tumour Cells In Vitro. Plenum Press: New York
21. Gold P, Freedman SO (1965) Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med 121: 439-462
22. Granowska M, Jass JR, Britton KE, Northover JM (1989) A prospective study of the use of 111In-labelled monoclonal antibody against carcinoembryonic antigen in colorectal cancer and of some biological factors affecting its uptake. Int J Colorectal Dis 4: 97-108
23. Hammarstrom S (1999) The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol 9: 67-81
24. Kubo A, Nakamura K, Katayama M, Hashimoto S, Teramoto T, Kodaira S (1992) Pharmacokinetic analysis of antibody localization in human colon cancer: comparison with immunoscintigraphy. Ann Nucl Med 6: 21-27
25. Lanier LL, Ruitenberg JJ, Phillips JH (1988) Functional and biochemical analysis of CD16 antigen on natural killer cells and granulocytes. J Immunol 141: 3478-3485
26. Liersch T, Meller J, Bittrich M, Kulle B, Becker H, Goldenberg DM (2007) Update of carcinoembryonic antigen radioimmunotherapy with (131)i-labetuzumab after salvage resection of colorectal liver metastases: comparison of outcome to a contemporaneous control group. Ann Surg Oncol 14: 2577-2590
27. Liljefors M, Nilsson B, Hjelm Skog AL, Ragnhammar P, Mellstedt H, Frodin JE (2003) Natural killer (NK) cell function is a strong prognostic factor in colorectal carcinoma patients treated with the monoclonal antibody 17-1A. Int J Cancer 105: 717-723
28. Lubeck MD, Steplewski Z, Baglia F, Klein MH, Dorrington KJ, Koprowski H (1985) The interaction of murine IgG subclass proteins with human monocyte Fc receptors. J Immunol 135: 1299-1304
29. Moretta A, Tambussi G, Ciccone E, Pende D, Melioli G, Moretta L (1989) CD16 surface molecules regulate the cytolytic function of CD3CD16+ human natural killer cells. Int J Cancer 44: 727-730
30. Motoyama T, Hojo H, Suzuki T, Oboshi S (1979) Evaluation of the regrowth assay method as an in vitro drug sensitivity test and its application to cultuered human gastric cancer cell lines. Acta Medica et Biologica 27: 49-63
31. Nimmerjahn F, Ravetch JV (2005) Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 310: 1510-1512
32. Olszewski AJ, Grossbard ML (2004) Empowering targeted therapy: lessons from rituximab. Sci STKE 2004: pe30
33. Paraskeva C, Buckle BG, Sheer D, Wigley CB (1984) The isolation and characterization of colorectal epithelial cell lines at different stages in malignant transformation from familial polyposis coli patients. Int J Cancer 34: 49-56
34. Reichert JM, Valge-Archer VE (2007) Development trends for monoclonal antibody cancer therapeutics. Nat Rev Drug Discov 6: 349-356
35. Richman PI, Bodmer WF (1987) Monoclonal antibodies to human colorectal epithelium: markers for differentiation and tumour characterization. Int J Cancer 39: 317-328
36. Solic N, Collins JE, Richter A, Holt SJ, Campbell I, Alexander P, Davies DE (1995) Two newly established cell lines derived from the same colonic adenocarcinoma exhibit differences in EGF-receptor ligand and adhesion molecule expression. Int J Cancer 62: 48-57
37. Spurr NK, Durbin H, Sheer D, Parkar M, Bobrow L, Bodmer WF (1986) Characterization and chromosomal assignment of a human cell surface antigen defined by the monoclonal antibody AUAI. Int J Cancer 38: 631-636
38. Stewart LM, Young S, Watson G, Mather SJ, Bates PA, Band HA, Wilkinson RW, Ross EL, Snary D (1999) Humanisation and characterisation of PR1A3, a monoclonal antibody specific for cell-bound carcinoembryonic antigen. Cancer Immunol Immunother 47: 299-306
39. Thompson JA, Grunert F, Zimmermann W (1991) Carcinoembryonic antigen gene family: molecular biology and clinical perspectives. J Clin Lab Anal 5: 344-366
40. Titus JA, Perez P, Kaubisch A, Garrido MA, Segal DM (1987) Human K/ natural killer cells targeted with hetero-cross-linked antibodies specifically lyse tumor cells in vitro and prevent tumor growth in vivo. J Immunol 139: 3153-3158
41. Tom BH, Rutzky LP, Jakstys MM, Oyasu R, Kaye CI, Kahan BD (1976) Human colonic adenocarcinoma cells. I. Establishment and description of a new line. In vitro 12: 180-191
42. Umana P, Jean-Mairet J, Moudry R, Amstutz H, Bailey JE (1999) Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat Biotechnol 17: 176-180
43. Watkins JF, Sanger C (1977) Properties of a cell line from human adenocarcinoma of the rectum. Br J Cancer 35: 785-794
44. Welt S, Divgi CR, Real FX, Yeh SD, Garin-Chesa P, Finstad CL, Sakamoto J, Cohen A, Sigurdson ER, Kemeny N (1990) Quantitative analysis of antibody localization in human metastatic colon cancer: a phase I study of monoclonal antibody A33. J Clin Oncol 8: 1894-1906
45. Wiratkapun S, Kraemer M, Seow-Choen F, Ho YH, Eu KW (2001) High preoperative serum carcinoembryonic antigen predicts metastatic recurrence in potentially curative colonic cancer: results of a five-year study. Dis Colon Rectum 44: 231-235
46. Wong JY, Chu DZ, Williams LE, Yamauchi DM, Ikle DN, Kwok CS, Liu A, Wilczynski S, Colcher D, Yazaki PJ, Shively JE, Wu AM, Raubitschek AA (2004) Pilot trial evaluating an 123I-labeled 80-kilodalton engineered anticarcinoembryonic antigen antibody fragment (cT84.66 minibody) in patients with colorectal cancer. Clin Cancer Res 10: 5014-5021